Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-11-033048
Filing Date
2011-05-31
Accepted
2011-05-31 06:19:25
Documents
8
Period of Report
2010-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT v224319_20f.htm 20-F 1319947
2 CONSULTING AGREEMENT v224319_ex10-51.htm EX-10.51 137314
3 OPTION TO LICENSE AGREEMENT v224319_ex10-52.htm EX-10.52 68420
4 LIST OF SUBSIDIARIES v224319_ex21-1.htm EX-21.1 5109
5 CONSENT OF KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIO v224319_ex23-1.htm EX-23.1 5783
6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A)/15D-14(A), v224319_ex31-1.htm EX-31.1 10009
7 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A)/15D-14(A), v224319_ex31-2.htm EX-31.2 9981
8 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT T v224319_ex32-1.htm EX-32.1 8762
  Complete submission text file 0001144204-11-033048.txt   1566342
Mailing Address 85 MEDINAT HAYEHUDIM ST. PITUACH, PO BOX 4033 HERZLIYA L3 46140
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

EIN.: 000000000
Type: 20-F | Act: 34 | File No.: 000-51310 | Film No.: 11879628
SIC: 2834 Pharmaceutical Preparations